RepliCel Life Sciences Inc.

OTC: REPCF · Healthcare · Biotechnology

Canadian filerHQ Vancouver, BCCIK 0001205059Reports USD

#1 of 1,394 Healthcare companies by revenue

EA Score

——

FH —DQ —GM —SS 26

v0.1 · 5/100 weight · pillars only

↑ Piotroski F, listing tenure · ↓ workforce scale, filing timeliness

Methodology →

Revenue TTM

$318.1k

Rev growth YoY (TTM)

+35.0%

Net income (FY)

-$571.2k

Employees

Market cap

$7.0k

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$571.2k-743.2k CAD2022

Total assets$589.4k798.2k CAD2022

Liabilities$5.0M6.7M CAD2022

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

RepliCel Life Sciences Inc. earned -$571.2k in FY2022 net income.

Peers · Healthcare

Nexien BioPharma, Inc.——Statera Biopharma, Inc.——FluoroPharma Medical, Inc.——WellQuest Medical & Wellness Corporation——

Key facts

CEOAndrew Schutte

SectorHealthcare

IndustryBiotechnology

HeadquartersVancouver, BC

ExchangeOTC: REPCF

Employees1

IPO date2010-05-03

Latest filings

6-K2024-03-20 6-K2023-11-30 6-K2023-10-24 6-K2023-10-19 6-K2023-10-04 6-K2023-09-14 6-K2023-09-07 6-K2023-08-30

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.